Common Contracts
2 similar Commercialization Agreement contracts
Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson’s Disease in JapanCommercialization Agreement • December 6th, 2020
Under the terms of the agreement, Kyowa Hakko Kirin will be responsible for commercializing the product after Hisamitsu Pharmaceutical receives a manufacturing and marketing approval for the product in Japan. Hisamitsu Pharmaceutical will receive an upfront payment and milestone payments based on the regulatory approval and the sales amount.
Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson’s Disease in JapanCommercialization Agreement • February 5th, 2019
Under the terms of the agreement, Kyowa Hakko Kirin will be responsible for commercializing the product after Hisamitsu Pharmaceutical receives a manufacturing and marketing approval for the product in Japan. Hisamitsu Pharmaceutical will receive an upfront payment and milestone payments based on the regulatory approval and the sales amount.
